Sam-A Pharm. Co., Ltd

KOSDAQ:A009300 Stock Report

Market Cap: ₩85.1b

Sam-A Pharm Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sam-A Pharm.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth20.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Apr 01

We Think That There Are More Issues For Sam-A Pharm (KOSDAQ:009300) Than Just Sluggish Earnings

Sam-A Pharm. Co., Ltd's ( KOSDAQ:009300 ) recent weak earnings report didn't cause a big stock movement. We think that...
Analysis Article • Dec 06

Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% Cheaper

The Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Nov 13

Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Aug 25

Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% Dive

Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have retraced a considerable 34% in the last month, reversing a fair...
Analysis Article • Jul 11

Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%

Despite an already strong run, Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) shares have been powering on, with a gain of 32...
Analysis Article • Jun 21

Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • May 25

Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The Market

The Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) share price has done very well over the last month, posting an excellent...
Analysis Article • Apr 08

Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its Dividend

Today we'll take a closer look at Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) from a dividend investor's perspective...
Analysis Article • Mar 04

Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 28

How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?

As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...
Analysis Article • Dec 24

Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend Date

It looks like Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) is about to go ex-dividend in the next 4 days. Investors can...
Analysis Article • Dec 07

Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?

Is Sam-A Pharm. Co., Ltd ( KOSDAQ:009300 ) a good dividend stock? How can we tell? Dividend paying companies with...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sam-A Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A009300 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202672,28510,54512,25514,279N/A
3/31/202670,9288,8877,8479,722N/A
12/31/202577,79912,9408,99510,723N/A
9/30/202576,65913,1878,94311,620N/A
6/30/202582,51815,34414,15818,157N/A
3/31/202590,12619,00016,07220,793N/A
12/31/202495,58122,08018,84425,247N/A
9/30/2024101,39322,76825,82732,527N/A
6/30/2024102,55024,74424,65530,253N/A
3/31/2024102,51123,93625,29430,074N/A
12/31/202397,21121,37417,20420,760N/A
9/30/202395,93120,33816,34218,144N/A
6/30/202395,32420,38715,49215,844N/A
3/31/202387,15915,53117,96717,536N/A
12/31/202281,70011,91220,46519,604N/A
9/30/202275,47911,02917,43115,629N/A
6/30/202266,1727,52017,81716,940N/A
3/31/202263,6387,00013,68312,874N/A
12/31/202154,6663,39213,71712,943N/A
9/30/202150,90717814,00513,670N/A
6/30/202150,870-1,1159,1489,078N/A
3/31/202148,548-1,6509,93710,177N/A
12/31/202053,6531249,0569,408N/A
9/30/202059,7753,39210,0049,389N/A
6/30/202064,0255,98614,96814,092N/A
3/31/202070,3469,128N/A13,867N/A
12/31/201971,56010,197N/A13,221N/A
9/30/201970,7159,807N/A14,334N/A
12/31/201866,9478,801N/A12,755N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A009300's forecast earnings growth is above the savings rate (3.3%).

Earnings vs Market: Insufficient data to determine if A009300's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A009300's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A009300's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A009300's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A009300's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/12 23:28
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sam-A Pharm. Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.